MuteFree AAV Launched

Adeno-associated virus is one of gene therapy’s main delivery tools, and VectorBuilder said on April 14 it has launched a redesigned version meant to make that tool easier to manufacture reliably. (vectorbuilder.com) In gene therapy, adeno-associated virus acts like a delivery shell that carries a therapeutic gene into cells. Most of the virus is removed, but two short DNA ends called inverted terminal repeats are left in place because they are needed for replication, packaging, and persistence. (nature.com) (pmc.ncbi.nlm.nih.gov) Those inverted terminal repeats are hard to keep intact because their folded, palindrome-like structure can mutate or break during plasmid amplification in bacteria. Reviews and experimental studies have described that instability as a recurring manufacturing problem for adeno-associated virus vectors. (mdpi.com) (biorxiv.org) VectorBuilder’s new construct, called MuteFree, is designed to produce adeno-associated virus vectors with mutation-free inverted terminal repeats while staying compatible with existing good manufacturing practice workflows, according to the company and a preprint posted on April 8. The company said the system is aimed at both higher fidelity and higher yield in production. (vectorbuilder.com) (biorxiv.org) The timing matters because adeno-associated virus remains one of the most widely used platforms in human gene therapy, but manufacturing scale-up and quality control still limit how quickly programs move from research to the clinic. A 2025 review called process complexity, cost, and rigorous quality testing persistent barriers for recombinant adeno-associated virus production. (nature.com) (sciencedirect.com) United States regulators already treat chemistry, manufacturing, and control data as a core part of gene therapy submissions. The Food and Drug Administration’s guidance for human gene therapy investigational new drug applications includes detailed expectations for manufacturing information and product characterization. (fda.gov) VectorBuilder said the technology is described in a manuscript on bioRxiv, a preprint server that posts papers before peer review. The preprint also states that all authors are affiliated with VectorBuilder and that the work is covered by pending patents owned by the company. (biorxiv.org) For gene therapy developers, the immediate question is whether a cleaner backbone can reduce one of the field’s routine failure points before batches reach formal release testing. VectorBuilder is framing MuteFree as an upstream manufacturing fix, not a new clinical result. (vectorbuilder.com)